BioNexus Gene Lab Corp. (BGLC)
Nasdaq · Basic Materials · Specialty Chemicals
$1.28+0.79%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $3.8M
- 52-week range
- $1.07 – $5.89
- 52-week change
- −75.72%
- EPS (trailing)
- −$1.27
Fiscal year to Dec 2025
- Revenue
- $7.4M (−21.93%)
- Net income
- −$3.0M
- Operating margin
- −39.9%
- Free cash flow
- −$1.9M
From the company’s annual report on SEC EDGAR.
About BioNexus Gene Lab Corp.
BioNexus Gene Lab Corp., together with its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding. It offers various chemical raw material products, including polyester resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; polyester resin 9509, a general-purpose material used in the production of marine boats and water slides; and polyester resin 2802, which is used as a component in the pultrusion process. The company's products are used in producing various finished goods, such as handrails, bench tops, and automotive and aero parts; paneling for hospital, laboratory, and industrial clean rooms; and covers for various instruments used in manufacturing. It develops and provides non-invasive liquid biopsy tests for the early detection of biomarkers. BioNexus Gene Lab Corp.
Headquarters: Kuala Lumpur, Malaysia · 19 employees · bionexusgenelab.com